
	Where results make sense

Topic: Warner Chilcott

Related Topics

Lists of companies

ISEQ

List of Irish companies

In the News (Wed 23 Dec 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

	Warner Chilcott - Wikipedia, the free encyclopedia
		Warner Chilcott (formerly Galen) is a Northern Irish pharmaceutical company.
		It is primarily focused on two core therapeutic areas: women’s healthcare and dermatology.
		In 2000, Galen acquired the Warner Chilcott US pharmaceutical company which is focused on women’s healthcare, and simultaneously listed its ADRs on NASDAQ.
	en.wikipedia.org /wiki/Warner_Chilcott (166 words)

	RTE Business - Warner Chilcott receives second approach
		Northern Ireland based drug company Warner Chilcott confirmed this morning that it has received an additional approach from a second interested party which may or may not lead to an offer for the company.
		Warner Chilcott, in a statement, said the new party has entered into a confidentiality agreement with the company and is beginning due diligence enquiries.
		Warner Chilcott specialises in women's health and urology.
	www.rte.ie /business/2004/1001/warner.html (180 words)

	RTE Business - Warner Chilcott confirms approach bid
		Northern Ireland based drugs company Warner Chilcott, which was formerly known as Galen Holdings, has confirmed that it has received an approach for the firm.
		In a statement this morning, Warner Chilcott said a consortium of private equity houses have made an approach for the company, which may or may not lead to an offer.
		The statement was in response to recent media speculation, Warner Chilcott said.
	www.rte.ie /business/2004/0920/warner.html (248 words)

	BioSpace News for Warner Chilcott (Site not responding. Last check: 2007-10-14)
		Warner Chilcott, plc (Nasdaq: WCRX) announced today that a meeting has been convened at the direction of the High Court of Ireland for the purpose of considering and approving the scheme of arrangement which will be used to implement the previously announced acquisition of Warner Chilcott by Galen Holdings PLC.
		Warner Chilcott, plc (Nasdaq: WCRX) today announced the termination of their co-promotion agreement with Schering-Plough Corporation for their cardiovascular products K-DUR(R), an extended-release potassium supplement and Nitro-Dur(R), a nitroglycerin patch for angina, as well as for Lotrisone(R), a topical combination antifungal/corticosteroid, effective September 30, 2000.
		Warner Chilcott has appointed Dr. Ellman to this newly created position to be responsible for U.S. clinical development activities in the women's health care area.
	www.acor.org /drugs/pipeline/companies/news/old/2862.news.orig (1063 words)

	FTC Pressures Warner Chilcott
		The FTC, 34 states and the District of Columbia previously sued Warner Chilcott for what they allege was an anticompetitive agreement in which Barr was the sole supplier to Warner Chilcott of an oral contraceptive called Ovcon 35.
		Shortly after midnight Tuesday, Warner Chilcott issued a press release saying that the FTC had filed a new legal motion which said the company's strategy would harm consumers because the Barr deal blocked the selling of a generic version of Ovcon 35.
		Warner Chilcott also said it will contest the new complaint by the FTC "vigorously." Because FTC's initial complaint focused primarily on the provisions with Barr that now have been waived, Warner Chilcott says it will seek to dismiss the FTC complaint.
	www.thestreet.com /newsanalysis/pharmaceuticals/10311266.html (408 words)

	Lead Plaintiff Deadline Approaching for Investors of Warner Chilcott Limited -- WCRX
		Warner Chilcott is engaged in the development, manufacture, sale and marketing of branded prescription pharmaceutical products in women's healthcare and dermatology, primarily in the United States.
		The complaint alleges that the Registration Statement issued in connection with the initial public offering ("IPO") of Warner Chilcott common stock, which took place on or about September 20, 2006, contained untrue statements of material facts and was not prepared in accordance with the rules and regulations governing its preparation.
		On September 26, 2006, Warner Chilcott announced developments in a lawsuit brought against it by the Federal Trade Commission and filed a supplement to the Registration Statement in which it disclosed that, among other things, it had ceased shipments of Ovcon 35 in September 2006 when it launched Ovcon Chewable.
	news.tradingcharts.com /futures/3/3/87081833.html (641 words)

	OAG: Press Release - November 7, 2005
		The antitrust lawsuits, filed November 7 in the US District Court for the District of Columbia, allege that Warner Chilcott paid Barr $20 million to keep it from marketing a generic version of Ovcon®.
		In response to this development, Warner Chilcott paid Barr $1 million in September 2003 for an option agreement.
		As a result of the option agreement, Warner Chilcott is the only company in the United States today that markets Ovcon®.
	occ.dc.gov /occ/cwp/view,a,11,q,634105,occNav_GID,1521.asp (307 words)

	Orange Book Blog: FTC Seeks to Force Warner Chilcott to Keep Marketing Ovcon 35
		In response to Warner Chilcott's formulation switch, the FTC filed a notice in the U.S. District Court for the District of Columbia (where it was already in litigation against Warner Chilcott over an authorized generic deal for Ovcon 35) that it intended to seek a preliminary injunction forcing Warner Chilcott to continue marketing Ovcon 35.
		Almost simultaneously with the FTC's filing of its motion for preliminary injunction, Warner Chilcott announced that it had canceled the exclusivity provisions of its Ovcon 35 authorized generic deal--a move intended to dispose of the litigation with the FTC.
		In the FTC's complaint in that case, the FTC alleged that an authorized generic deal between Warner Chilcott and Barr for Ovcon 35 was anticompetitive, in violation of Section 5(a) of the FTC Act.
	www.orangebookblog.com /2006/09/ftc_seeks_to_co.html (442 words)

	News: Warner Chilcott Sues Watson for Infringement of Loestrin(R) 24 Fe Patent. Genetic Engineering News - ...
		News: Warner Chilcott Sues Watson for Infringement of Loestrin(R) 24 Fe Patent.
		District Court for the District of New Jersey alleging infringement of Warner Chilcott's U.S. patent that protects Loestrin(R) 24 Fe.
		The lawsuit is in response to an Abbreviated New Drug Application filed by Watson with the FDA regarding Watson's intent to market a generic version of Loestrin(R) 24 Fe prior to the expiration of Warner Chilcott's U.S. Patent No. 5,552,394.
	www.genengnews.com /news/bnitem.aspx?name=3981211 (358 words)

	Warner Chilcott - Investor FAQs
		Warner Chilcott Limited's Class A Common Shares are traded on the NASDAQ Global Market.
		If you are interested in purchasing Warner Chilcott stock, please consult the stockbroker or stock purchase service of your choice.
		Warner Chilcott releases its earnings results as soon as practical following each of these dates within the bounds of required reporting dates as defined by the Securities and Exchange Commission.
	ir.wcrx.com /faq.cfm (328 words)

	Biocompare News - Warner Chilcott Licenses Worldwide Rights To Schering AG's SEGRA Compound For Dermatologic ...
		Warner Chilcott Limited announced today that Schering will license to Warner Chilcott its proprietary selective glucocorticoid receptor agonist (SEGRA) compound for the oral or topical treatment of inflammatory skin diseases.
		Warner Chilcott will pay a royalty to Schering on sales of any product containing the SEGRA compound under the license.
		Warner Chilcott is a leading specialty pharmaceutical company focused on developing, manufacturing, marketing and selling branded prescription products in the women's healthcare and dermatology therapeutic categories in the United States.
	news.biocompare.com /newsstory.asp?id=159661 (418 words)

	U.S. Sues Two Drug Firms for Delaying Generic Birth-Control Pill
		"The agreement between Warner Chilcott and Barr is a naked agreement not to compete and to share the resulting profits between a branded drug seller and its only prospective generic competitor," FTC Chairman Deborah Platt Majoras said in a statement.
		Warner Chilcott said in a statement that it is "disappointed" by the FTC's decision to sue the company.
		In its statement, Warner Chilcott said the FTC examined its agreement with Barr two years ago and did not find any problem with it.
	news.findlaw.com /andrews/h/hea/20051219/20051219warner.html (692 words)

	Department of Justice, State of Oregon - Media Release
		Attorney General Hardy Myers today sued Warner Chilcott Corporation and Barr Pharmaceuticals, Inc. in the United States District Court for the District of Columbia for entering into an agreement, which blocked generic competition for Warner Chilcott’s oral contraceptive Ovcon®.
		Once Warner Chilcott made this payment, Barr would be prevented from coming to market with generic Ovcon®.
		According to Attorney General Myers, "Warner Chicott and Barr are engaging in a restraint of trade that hurts consumers, in violation of the antitrust laws of the United States and various other states, including Oregon.
	www.doj.state.or.us /releases/2005/rel110805.shtml (437 words)

	[No title] (Site not responding. Last check: 2007-10-14)
		Under the agreement, Warner Chilcott's reps will utilize Dendrite's ForceMobile™ solution; its district managers will use ForceAnalyzeRx®; and the company's home office personnel will deploy Dendrite's newest solutions, SampleEnforcer™ and Validator™.
		"Pharmaceutical companies like Warner Chilcott are increasingly turning to Dendrite to develop innovative solutions for their present and future sales force requirements," said Mark Cieplik, Dendrite Senior Vice President of Global Sales.
		Warner Chilcott, a division of Galen Holdings plc, is a marketer of prescription pharmaceutical products in the United States, focused on women's health care, dermatology, and urology.
	www.dendrite.com /index.aspx?page_id=190 (573 words)

	Warner Chilcott Falls in Debut
		Warner Chilcott (WCRX - news - Cramer's Take), a developer of women's health products, has priced its initial public offering of 70.6 million shares at $15 each, below its expected range of $17 to $19 a share.
		Shares of Warner Chilcott were lower near the end of their first trading day, falling 15 cents, or 1%, to $14.85.
		Warner Chilcott, a maker of contraceptives and hormone therapies, as well as dermatologic drugs for psoriasis and acne, expects to launch the first Food and Drug Administration-approved chewable oral contraceptive, Ovcon 35 Fe, this month.
	www.thestreet.com /newsanalysis/healthcare/10310355.html (199 words)

	Orange Book Blog: FTC and Warner Chilcott Settle Antitrust Case Over Ovcon 35
		The FTC and Warner Chilcott have settled antitrust charges alleging anticompetitive behavior involving Warner Chilcott's popular birth control drug Ovcon 35.
		The FTC filed the case to nullify a reverse payment agreement between Warner Chilcott and Barr Laboratories that would have prevented Barr from launching a generic version of Ovcon 35 until May, 2009.
		The [settlement] came shortly after Warner Chilcott abandoned – under threat of a preliminary injunction sought by the FTC – the portion of its agreement with Barr Laboratories that prevented Barr from bringing a generic version of the drug to the market.
	www.orangebookblog.com /2006/10/ftc_and_warner_.html (350 words)

	Warner Chilcott
		Appointment of James H. Bloem as Director of Warner Chilcott Limited
		Warner Chilcott to Present at the Credit Suisse Healthcare Conference
		Warner Chilcott Licenses Worldwide Rights to Schering AG's SEGRA Compound for Dermatologic Indications and Announces Settlement of Yaz(R) Patent Litigation
	www.warnerchilcott.com (59 words)

	Lerach Coughlin \| Warner Chilcott \| Press Release
		The complaint charges Warner Chilcott and certain of its officers and directors with violations of the Securities Act of 1933.
		According to the complaint, the Registration Statement issued in connection with the IPO contained untrue statements of material facts, omitted to state other facts necessary to make the statements made not misleading and was not prepared in accordance with the rules and regulations governing its preparation.
		Plaintiff seeks to recover damages on behalf of all those who purchased the common stock of Warner Chilcott pursuant and/or traceable to the Company’s initial public offering on or about September 20, 2006 through September 26, 2006.
	www.lerachlaw.com /lcsr-cgi-bin/mil?case=warnerchilcott (479 words)

	Warner Chilcott Files for Billion I.P.O. - Mergers, Acquisitions, Venture Capital, Hedge Funds -- DealBook - New York ...
		Warner Chilcott Holdings, an Irish pharmaceuticals company that was the subject of a bitter takeover battle between private equity groups in 2004, has filed to raise as much as $1 billion in an initial public offering of stock.
		The auction of Warner Chilcott in 2004 shook the private equity industry because it laid bare the conflicts that can arise when investment banks use their buyout arms to bid for companies.
		The DLJ group won Warner Chilcott for $3 billion, but it ended up creating friction with Blackstone.
	dealbook.blogs.nytimes.com /?p=4050 (374 words)

	PRESS RELEASE Yourman Alexander & Parekh LLP Announces Class Action Lawsuit Against Warner Chilcott Ltd. (Site not responding. Last check: 2007-10-14)
		If you purchased or acquired Warner securities during the Class Period and either continue to hold those securities or sold them at a loss, the deadline to move for appointment as Lead Plaintiff is January 2, 2007.
		A Lead Plaintiff is the person or entity that the Court appoints to take a leadership role in prosecuting the case and to represent the interests of other similarly injured class members.
		Six days later, when Warner finally disclosed this fact, and after it had already conducted its offering, Warner shares plummeted from approximately $15.00 per share to $12.60 per share.
	www.marketwire.com /mw/release_html_b1?release_id=190143 (362 words)

	In The Courts \| Warner Chilcott, Schering Reach Settlement in Patent Lawsuit Over Oral Contraceptive YAZ - ...
		Warner Chilcott, Schering Reach Settlement in Patent Lawsuit Over Oral Contraceptive YAZ
		United Kingdom-based pharmaceutical company Warner Chilcott on Tuesday announced it has reached a settlement in a lawsuit the company filed in a U.S. District Court in New Jersey claiming Germany-based Schering's low-dose oral contraceptive YAZ infringed on a Chilcott patent,
		Chilcott in March announced it had filed the lawsuit against Schering and its subsidiary Berlex for violating the U.S. patent of Chilcott's recently FDA-approved Loestrin 24 Fe contraceptive in the marketing of YAZ.
	www.kaisernetwork.org /daily_reports/rep_index.cfm?DR_ID=41080 (196 words)

	PRESS RELEASE Abraham Fruchter & Twersky LLP Files Class Action Lawsuit Against Warner Chilcott Ltd. (Site not responding. Last check: 2007-10-14)
		The Company's Registration Statement and Prospectus issued in connection with the IPO failed to disclose that shortly prior to the IPO, the Company had stopped shipping Ovcon 35, Warner Chilcott's top selling birth control pill and a primary source of revenue for the Company.
		On this news, Warner Chilcott's common stock price closed at $12.60 a share, on unusually high volume of nearly 15 million shares traded, down $2.40 a share from the offering price of $15 per share.
		If you purchased or otherwise acquired the publicly traded common stock of Warner Chilcott pursuant and/or traceable to the Company's Registration Statement and Prospectus issued in connection with the IPO, you may, no later than January 7, 2007, request that the Court appoint you as lead plaintiff.
	www.marketwire.com /mw/release_html_b1?release_id=182644 (448 words)

	Court Enters Final Order Settling FTC’s Charges Against Warner Chilcott
		U.S. District Court Judge Colleen Kollar-Kotelly yesterday entered a final order settling the Federal Trade Commission’s charges that drug company Warner Chilcott’s agreement with Barr Laboratories unlawfully delayed entry of Barr’s generic version of Warner Chilcott’s Ovcon birth control pill.
		Last month, under threat of a preliminary injunction sought by the FTC, Warner Chilcott abandoned the portion of its agreement with Barr that prevented Barr from bringing a generic version of Ovcon to the market.
		Warner Chilcott Holdings Company III, Ltd.; Warner Chilcott Corporation; Warner Chilcott (US) Inc.; Galen (Chemicals) Ltd.; and Barr Pharmaceuticals, Inc. (U.S. District Court for the District of Columbia); Civil Action No. 1:05-cv-02179-CKK; FTC File No. 041 0034
	www.ftc.gov /opa/2006/10/chilcottorder.htm (411 words)

	Warner Chilcott PLC Jobs: Vault Jobs & Employment Profiles (Site not responding. Last check: 2007-10-14)
		Warner Chilcott PLC Jobs: Vault Jobs & Employment Profiles
		With employee surveys, company profiles, job listings, message boards and more, Vault is your complete resource to jobs and employment at Warner Chilcott PLC.
		Warner Chilcott PLC employee surveys are collected by Vault editors, Vault Gold Surveys provide detailed information on jobs and employment at specific employers.
	www.vault.com /jobs-company/Warner-Chilcott-PLC.html (146 words)

	Healthcare Sales & Marketing Network News: Barr Announces Warner Chilcott Waives Exclusive License for OVCON(R) 35
		"Today's action by Warner Chilcott paves the way for Barr to launch the first generic version of OVCON 35," said Bruce L. Downey, Barr's CEO and Chairman.
		In March 2004, the Company granted Warner Chilcott an option to acquire an exclusive license under Barr's Abbreviated New Drug Application (ANDA) for OVCON 35 oral contraceptive.
		In May 2004, Warner Chilcott exercised its option to acquire an exclusive license for Barr's generic version of OVCON 35 oral contraceptive option and was granted a five-year exclusive license to sell the product under Barr's ANDA.
	salesandmarketingnetwork.com /news_release.php?ID=2013768 (645 words)

	Schatz Nobel Izard, P.C. Announces Class Action Lawsuit Against Warner Chilcott Limited -- WCRX (Site not responding. Last check: 2007-10-14)
		The Complaint alleges that Warner Chilcott and certain of its officers and directors violated federal securities laws by issuing a series of materially false statements.
		Specifically, the Registration Statement issued in connection with the IPO contained untrue statements of material facts, omitted to state other facts necessary to make the statements made not misleading and was not prepared in accordance with the rules and regulations governing its preparation.
		The complaint alleges that the Registration Statement failed to disclose that at the time of the IPO, Warner Chilcott had ceased shipments of Ovcon 35, its top selling birth control pill, thereby eliminating a primary revenue stream for the Company.
	research.investopedia.com /news/PrimeZone/99064108022.aspx (629 words)

Try your search on: Qwika (all wikis)